INGR vs JBS
Ingredion vs Jbs N.V. — AI-powered side-by-side comparison
| Metric | INGR | JBS |
|---|
| AI Score |
62
|
61
|
| Price |
$104.70
|
$13.03
|
| P/E Ratio |
11.25×
|
17.96×
|
| ROE |
16.8%
|
23.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
23.7%
|
11.9%
|
| Debt / Equity |
0.39×
|
0.00×
|
| Dividend Yield |
3.1%
|
7.7%
|
| RSI (14) |
57.8
|
41.6
|
| Beta |
0.606
|
0.1605
|
| Expected Upside |
+1.6%
|
—
|
AI Committee View
Current Innellis committee reasoning for INGR versus JBS.
INGR leads by 1 points.
INGR scores 62/100 (Buy) versus JBS at 61/100 (Buy).
INGR Committee View
60% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is revenue declining -1.4% yoy -- this is not a growth story right now. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 11.1 is inexpensive for the broad market — Value
- Dividend yield of 3.2% pays you to wait — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Revenue declining -1.4% YoY -- this is not a growth story right now — Growth
- EPS declining -10.3% YoY despite any revenue growth — Growth
JBS Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 48.5% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 2.65) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- P/E of 8.2 is inexpensive for the broad market — Value
- ROE of 20.5% shows genuine earnings power backing the valuation — Value
- Dividend yield of 14.9% pays you to wait — Value
Bear Case
- Debt-to-equity of 2.65 adds balance-sheet risk to the value case — Value
- MACD histogram negative -- bearish momentum — Technical
- High leverage (debt-to-equity 2.65) amplifies downside in a stress scenario — Risk